Test-Retest Reliability of the Patient Activation Measure-13 in Adults with Substance Use Disorders and Schizophrenia Spectrum Disorders

Katrine Melby, Mona Nygård, Mathias Forsberg Brobakken, Rolf W. Gråwe, Ismail Cüneyt Güzey, Solveig Klæbo Reitan, Einar Vedul-Kjelsås, Jørn Heggelund and Mariela Loreto Lara-Cabrera
Additional contact information
Katrine Melby: Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
Mona Nygård: Department of Mental Health, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
Mathias Forsberg Brobakken: Department of Mental Health, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
Rolf W. Gråwe: Department of Mental Health, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
Ismail Cüneyt Güzey: Department of Mental Health, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
Solveig Klæbo Reitan: Department of Mental Health, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
Einar Vedul-Kjelsås: Department of Mental Health, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway
Jørn Heggelund: Regional Center for Healthcare Improvement, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway
Mariela Loreto Lara-Cabrera: Department of Mental Health, Norwegian University of Science and Technology (NTNU), 7491 Trondheim, Norway

IJERPH, 2021, vol. 18, issue 3, 1-8

Abstract: Patient Activation Measure-13 (PAM-13) is a valid and widely used questionnaire that assess an individual’s knowledge, confidence, and skills for self-management of their chronic illness. Although there is some evidence regarding its reliability, the test–retest reliability has not been investigated among patients with substance use disorders (SUDs) or schizophrenia spectrum disorders. We investigated the internal consistency and test–retest reliability of PAM-13 in these populations. Test–retest reliability was analysed using data from 29 patients with SUDs and 28 with schizophrenia spectrum disorders. Cronbach’s α and Intraclass Correlation Coefficient (ICC) scores were used to examine internal consistency and test–retest reliability, respectively. Of the 60 collected test–retest questionnaires, 57 were included in the analyses. No mean differences between time one (T1) and time two (T2) were observed in either patient group, except for item 12 in schizophrenia spectrum disorders patients ( p < 0.05). Internal consistency for T1 and T2 was 0.75 and 0.84 in SUDs patients and 0.87 and 0.81 in schizophrenia spectrum disorders patients, respectively. The ICC was r = 0.86 in patients with SUDs and r = 0.93 in patients with schizophrenia spectrum disorders. To conclude, PAM-13 showed good internal consistency and test–retest reliability in SUDs and schizophrenia spectrum disorders patients.

Keywords: patient activation measure-13; internal consistency; test–retest reliability; self-management; schizophrenia spectrum disorders; substance use disorder (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/3/1185/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/3/1185/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:3:p:1185-:d:489105

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().